Aussie8 – Lifestyle
Author:
Structure Therapeutics Inc.
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 8, 2026
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
April 27, 2026
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
April 14, 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
March 16, 2026